US Healthcare Professionals

Now Approved:
Same Evrysdi, now in tablet form

For illustrative purposes only.

See new option

Evrysdi is designed to help produce SMN protein throughout the body

Evrysdi is designed to help produce
SMN protein throughout the body

The human body needs a key protein called survival motor neuron, or SMN, for our muscles to function properly

People living with SMA have low levels of this protein, causing muscles to break down

Evrysdi is a small molecule that is taken orally and is designed to reach areas of the body that need SMN protein such as*:

*When studied in animals, Evrysdi was distributed throughout the body.

GI stands for gastrointestinal.

Evrysdi works daily for a consistent impact on SMN protein levels

Within 4 weeks of treatment with Evrysdi, SMN protein levels in the blood approximately doubled, and they were maintained for Types 1, 2, and 3 SMA throughout 2 years of the pivotal studies†

Increased SMN icon
SMN doubled icon

 

†No data available in presymptomatic SMA (under 2 months).

See Evrysdi in Action icon
See Evrysdi in action
For adults and children
For infants
For presymptomatic SMA
learn more icon

Learn more about Evrysdi

Download
hear from others icon

Explore community videos

Hear community perspectives on Evrysdi 

Watch

Important Safety Information and Indication

What is Evrysdi?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.

  • Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:
    • are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine
    • are a woman who can become pregnant:
      • Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
      • Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
      • Pregnancy Registry. There is a pregnancy registry for women who take Evrysdi during pregnancy. The purpose of this registry is to collect information about the health of the pregnant woman and her baby. If you are pregnant or become pregnant while receiving Evrysdi, tell your healthcare provider right away. Talk to your healthcare provider about registering with the Evrysdi Pregnancy Registry. Your healthcare provider can enroll you in this registry or you can enroll by calling 1-833-760-1098 or visiting www.evrysdipregnancyregistry.com.
    • are an adult male. Evrysdi may affect a man’s ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
    • are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby
  • Tell your healthcare provider about all the medicines you take
  • If you were prescribed Evrysdi for Oral Solution, you should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement
  • Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
  • The most common side effects of Evrysdi include:
    • For later-onset SMA:
      • fever
      • diarrhea
      • rash
    • For infantile-onset SMA:            
      • fever
      • diarrhea
      • rash
      • runny nose, sneezing, and sore throat (upper respiratory infection)
      • lung infection (lower respiratory infection)
      • constipation
      • vomiting
      • cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

    • Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.

      Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.